News
VNRX
2.150
-2.71%
-0.060
InMed, AirSculpt top healthcare gainers; BrainsWay, Brookdale among losers
Seekingalpha · 11/16 15:01
VolitionRX reports Q3 results
Seekingalpha · 11/14 23:52
BRIEF-VolitionRx Says Cash, Cash Equivalents As Of Sep 30, 2022, Totaled About $16.4 Mln Compared With $16.7 Mln At Quarter Ended June 30, 2022
Reuters · 11/14 21:50
VolitionRx Ended Q3 With $16.7M Cash And Equivalents
Benzinga · 11/14 21:35
Volition Announces Clinical Research Study with Oncovet
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.
PR Newswire · 11/14 13:30
Notable earnings after Monday's close
Seekingalpha · 11/13 22:34
Volition Announces The Launch Of The Nu.Q® Vet Cancer Screening Test In The U.S. And Europe Through Heska's Reference Laboratories
Benzinga · 11/03 12:41
Volition Announces The Launch of the Nu.Q Vet Cancer Screening Test In The U.S. And Europe Through Heska's Reference Laboratories; VolitionRX Signs Exclusive $28M License And Supply Agreement With Heska
Benzinga · 11/03 12:37
Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its Nu.Q® Vet Cancer Screening Test across the U.S. and the forthcoming launch in Europe by Heska Corporation (NASDAQ: HSKA) ("Heska"), a l...
PR Newswire · 11/03 12:30
VNRX: Global Supply Agreement for Nu.Q Vet Cancer Test with a market leader in pet healthcare. U.S. Clinical studies for Nu.Q NETs are planned to pave the way for FDA approval.
By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT RECENT EVENTS THUS FAR DURING 2H/2022 Highlights Volition (NYSE:VNRX), a multi-national epigenetics company, is focusing on developing diagnostic blood tests (assays) that can help detect ...
Zacks Small Cap Research · 11/03 12:10
Why Super Micro Computer Shares Jumped Over 10%; Here Are 73 Biggest Movers From Yesterday
Benzinga · 10/21 08:36
Why Ericsson Shares Are Trading Lower? Here Are 56 Stocks Moving In Thursday's Mid-Day Session
Benzinga · 10/20 17:17
ASTI, CABA and PEGY among mid-day movers
Seekingalpha · 10/20 17:04
Volition Signs Global Supply Agreement For Nu.Q Vet Cancer Test
Benzinga · 10/20 12:17
Xenetic Biosciences, Inc. Announces Signing Of Patent Assignment Related To Collaboration With VolitionRx Limited And CLS Therapeutics
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced the
Benzinga · 10/11 12:08
Maxim Group Maintains Buy on VolitionRX, Lowers Price Target to $5
Maxim Group analyst Jason McCarthy maintains VolitionRX (AMEX:VNRX) with a Buy and lowers the price target from $8 to $5.
Benzinga · 08/23 13:19
BRIEF-Volitionrx Says Board Passed A Resolution To Increase Size Of Board To Nine Members
BRIEF-Volitionrx Says Board Passed A Resolution To Increase Size Of Board To Nine Members
Reuters · 08/16 22:30
Sidoti's August Micro-Cap Virtual Conference
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 17-18, 2022.
ACCESSWIRE · 08/16 19:00
BRIEF-VolitionRX appoints Mickie Henshall as an independent director
BRIEF-VolitionRX appoints Mickie Henshall as an independent director
Reuters · 08/16 12:14
Volition Appoints Mickie Henshall as an Independent Director
VolitionRx Limited (NYSE: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Mickie Henshall to its board of directors effective August 15, 2022. Ms. Henshall was also appointed as a member of the Compensation Commit...
PR Newswire · 08/16 12:00
More
Webull provides a variety of real-time VNRX stock news. You can receive the latest news about Volitionrx through multiple platforms. This information may help you make smarter investment decisions.
About VNRX
VolitionRx Limited is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop blood tests to help diagnose and monitor a range of diseases, including certain cancers and diseases associated with NETosis, such as sepsis and COVID-19. The Company’s tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids. Its Nucleosomics technology uses chromosomal structures called nucleosomes as biomarkers in cancer and other diseases. Its key pillars include Nu.Q , Nu.Q NETs, Nu.Q Capture, Nu.Q Discover and Nu.Q Vet. Its Nu.Q family of tests acts as an early warning system by monitoring treatment response, disease progression and remission. Its Nu.Q tests use epigenetic information from tumor cells nucleosomes that helps physicians select the treatment for each patient, monitor their response and disease progression.